Mwilson. The share price fell below $1 on concerns the FDA would restrict sales of testosterone products. In the end all they have done is to require some as yet unspecified labelling changes. The last sales quarters results were very encouraging. As such I see no reason why we should not see $1+ if the next quarter is also good. As it stands I think ACR currently has a very good risk reward ratio. Of course if you had bought some years ago you probably view things differently.
Add to My Watchlist
What is My Watchlist?
